Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.64 |
| ▸ | ITGB6 | P18564 | 18/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21317548 | 1.00 | ITGAV (0.64) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL28744031 | 1.00 | ITGAV (0.64) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL20141635 | 0.93 | ITGAV (0.72) | ITGAVITGB6ITGB3ITGB5 | |
| SCHEMBL20141631 | 0.93 | ITGAV (0.72) | ITGAVITGB6ITGB3ITGB5 | |
| SCHEMBL20158234 | 0.90 | ITGAV (0.62) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL30487502 | 0.88 | ITGAV (0.53) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL21826738 | 0.84 | ITGAV (0.87) | ITGAVITGB6 | |
| SCHEMBL21825970 | 0.84 | ITGAV (0.87) | ITGAVITGB6 | |
| SCHEMBL31125621 | 0.84 | ITGAV (0.87) | ITGAVITGB6 | |
| SCHEMBL21826141 | 0.84 | ITGAV (0.87) | ITGAVITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | ITGAV 4/4885ITGB6 12/4885ITGB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.